All In Biotech

Drug Trial Radar · NCT03075696

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

A Multicenter, Open-label, Phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

940

Planned (sponsor's estimate)

Start

Feb 21, 2017

Primary completion

Mar 30, 2029

Study completion Mar 30, 2029

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following pre-treatment with a one-time, fixed dose of obinutuzumab. This entry-into-human (EIH) study is divided in 3 parts: dose escalation (Parts I and II) and dose expansion (Part III). Single-participant dose-escalation cohorts will be used in Part I, followed by conversion to multiple participant dose-escalation cohorts (Part II), in order to define a tentative maximum tolerated dose (MTD) or optimal biological dose (OBD). The expansion cohorts (Part III) will be initiated when the tentative MTD/OBD is defined, to further evaluate the safety, PK and therapeutic activity of glofitamab.

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

  • GlofitamabDrug

    Glofitamab will be administered at a dose and as per the schedule specified in the respective arms.

  • ObinutuzumabDrug

    Obinutuzumab 1000 mg single dose IV infusion on Day -7; or 2000 mg single dose administered on Day -7, or split into two 1000 mg doses administered on Days -1 and -7, and per the schedule specified in the respective arms.

  • TocilizumabDrug

    Tocilizumab will be administered as an IV infusion, if required, for the management of severe Cytokine Release Syndrome (CRS) occurring during or after any infusion of glofitamab, as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part I and II: Percentage of Participants With Dose Limiting Toxicities (DLTs)Time frame: From Baseline up to 4 weeks
  2. Part I, II and III: Percentage of Participants With Adverse Events (AEs)Time frame: From Baseline up to 90 days after last dose of study drug or until study completion or participant withdrawal (up to 5 years)
  3. Part II: MTD or OBD of GlofitamabTime frame: From Baseline up to 4 weeks
  4. Part II: Recommended Phase II Dose (RP2D) of GlofitamabTime frame: From Baseline up to 5 years
  5. Part III: Complete Response (CR) Rate as Assessed by Independent Review Committee (IRC) According to Standard Non-hodgkin's Lymphoma (NHL) Response Criteria (Lugano Classification)Time frame: From treatment start up to 5 years
  6. Part I, II and III: Area Under the Serum Concentration Versus Time Curve (AUC) of GlofitamabTime frame: At pre-defined intervals from Cycle 1 Day 1 to Day 71
  7. Part I, II and III: Maximum Serum Concentration (Cmax) of GlofitamabTime frame: At pre-defined intervals from Cycle 1 Day 1 to Day 198
  8. Part I, II and III: Minimum Serum Concentration (Cmin) of GlofitamabTime frame: At pre-defined intervals from Cycle 1 Day 1 up to Day 198
  9. Part I, II and III: Clearance (CL) of GlofitamabTime frame: At pre-defined intervals from Cycle 1 Day 1 to Day 71
  10. Part I, II and III: Volume of Distribution at Steady-state (Vss) of GlofitamabTime frame: At pre-defined intervals from Cycle 1 Day 1 to Day 71
  11. Part I, II and III: Half-life (t1/2) of GlofitamabTime frame: At pre-defined intervals from Cycle 1 Day 1 to Day 71

Locations

34 sites in 13 countries. Site status is shown where the registry gives one.

  • University of Michigan

    Ann Arbor, Michigan

  • Washington University

    St Louis, Missouri

  • Mount Sinai Medical Center

    New York, New York

  • MSKCC

    New York, New York

  • Allegheny Health Network (Pittsburg PA)

    Pittsburgh, Pennsylvania

  • Swedish Cancer Inst.

    Seattle, Washington

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • UZ Gent

    Ghent, Belgium

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada

  • Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK

    Prague, Czechia

  • Rigshospitalet

    København Ø, Denmark

  • Helsinki University Central Hospital

    Helsinki, Finland

  • Hopital Henri Mondor

    Créteil, France

  • Hopital Claude Huriez

    Lille, France

  • CHU Saint Eloi

    Montpellier, France

  • Ch Lyon Sud

    Pierre-Bénite, France

  • CHU DE RENNES - CHU Pontchaillou

    Rennes, France

  • AUSL della Romagna

    Ravenna, Emilia-Romagna, Italy

  • Fond. IRCCS Istituto Nazionale Tumori

    Milan, Lombardy, Italy

  • Istituto Clinico Humanitas

    Rozzano, Lombardy, Italy

  • Auckland Cancer Trial Centre

    Auckland, New Zealand

  • Uniwersyteckie Centrum Kliniczne

    Gda?sk, Poland

  • Uniwersytecki Szpital Kliniczny w Poznaniu

    Późna, Poland

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu

    Wroc?aw, Poland

  • Hospital del Mar

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Univ. 12 de Octubre

    Madrid, Spain

  • Hospital Universitari Germans Trias i Pujol

    Badalona, Barcelona, Spain

  • Hospital Duran i Reynals L'Hospitalet

    L'Hospitalet de Llobregat, Barcelona, Spain

  • Hospital Universitario Marques de Valdecilla

    Santander, Cantabria, Spain

  • China Medical University Hospital

    Taichung, Taiwan

  • National Taiwan Universtiy Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.